Caribou Biosciences, Inc.
Caribou Biosciences, Inc.
Your view on CRBU
Overview
What the company does, where it operates, and who runs it.
About Caribou Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rachel E. Haurwitz
- Headquarters
- 2929 7th Street, Berkeley, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rachel E. Haurwitz
- Headquarters
- 2929 7th Street, Berkeley, CA, US
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.
The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies.
The company was incorporated in 2011 and is headquartered in Berkeley, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Caribou Biosciences, Inc., and the rating behind it. CRBU last traded at $1.27; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Caribou Biosciences, Inc.. Starting points for Caribou Biosciences, Inc.: EPS -$1.02, beta 2.28 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Caribou Biosciences, Inc.. Caribou Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Caribou Biosciences, Inc.. Trailing twelve-month EPS for Caribou Biosciences, Inc. stands at -$1.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Caribou Biosciences, Inc.. Caribou Biosciences, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Caribou Biosciences, Inc. valued side by side against its closest peers. Caribou Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Caribou Biosciences, Inc., and how their positions are changing. At a $126.0M market value, institutional positions materially move Caribou Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Caribou Biosciences, Inc. executives and directors. Shares of Caribou Biosciences, Inc. have traded between $0.66 and $3.54 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Caribou Biosciences, Inc.. Caribou Biosciences, Inc. is a $126.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Caribou Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Caribou Biosciences, Inc.. Coverage tracks Caribou Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.